Panacea Biotec Share Price Today

Panacea Biotec AGM: All resolutions passed with over 99% majority

All five resolutions at Panacea Biotec's 42nd AGM passed with requisite majority. Adoption of FY26 financial statements received 99.9632% votes in favour. Appointment of Rajinder Singh Manku as independent director approved as a special resolution. Voting results filed with exchanges on October 1, 2026, pursuant to SEBI regulations.

Panacea Biotec receives fresh ₹4.32 crore tax demand for alleged misreporting

Panacea Biotec received new tax demand orders totaling ~₹4.32 crore on September 29, 2026. The demands relate to alleged misreporting for Assessment Years 2022-23 and 2023-24. This adds to earlier demands of ₹9.82 crore for assessment years 2014-15 to 2018-19. Company plans to appeal, stating no significant financial or operational impact expected.

Panacea Biotec files FY26 BRSR report on voluntary basis

Panacea Biotec filed its BRSR for FY26 ended March 31, 2026. Company voluntarily complies with SEBI norms despite falling outside top 1,000 list. Pharmaceutical manufacturing contributes 100% of total turnover. Paid-up capital stands at ₹222,620,746. No third-party assurance was obtained for the report.

Panacea Biotec sets Sept 29 for 42nd AGM; book closure starts Sept 25

Panacea Biotec holds 42nd AGM on September 29, 2026, via video conferencing at 11:30 am. Register of members closes from September 25 to September 29, 2026. Shareholders vote on re-appointment of directors Ankesh Jain and Harshet Jain. Rajinder Singh Manku appointed as independent director for five-year term starting July 1, 2026. Cost auditor fee ratified at ₹1,25,000 for FY27.

Panacea Biotec AGM set for September 29 via video conference

Panacea Biotec Limited will hold its 42nd AGM on September 29, 2026, via VC/OAVM. The meeting aims to adopt FY25-26 financials. Shareholders must register emails with RTA Skyline Financial Services to access notices and e-voting credentials. Physical shareholders are urged to update details to participate effectively.

Panacea Biotec Q1 Results: Net profit falls 44% YoY to ₹23M

Panacea Biotec's Q1 results show a mixed bag with revenue rising to ₹2 billion from ₹1.7 billion YoY, but net profit dropping significantly to ₹23 million from ₹41 million. The data highlights margin compression as costs outpaced revenue growth.